SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PSDV - pSivida Limited
PSDV 1.220+14.0%Mar 29 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy9/9/2010 10:27:37 AM
   of 421
 
pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference

BOSTON--(BUSINESS WIRE)--pSivida Corp, (NASDAQ:PSDV - News)(ASX:PSD - News), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions,

today announced that it will webcast a live presentation at the Rodman & Renshaw Annual Health Care Conference in New York, Monday, September 13. Dr. Paul Ashton, President and Chief Executive Officer of pSivida, will present at 2:00 p.m. Eastern time.

A live audio webcast of the presentation will be available at wsw.com as well as at the company’s website: www.psivida.com. A replay of the presentation will be available at the company’s website for 90 days.

The company recently announced that the FDA has granted Priority Review status for the New Drug Application (NDA) filed for Iluvien®, its drug for diabetic macular edema that has been licensed to Alimera Sciences. As a result, pSivida believes that a response from the FDA regarding Iluvien could be received in the fourth quarter of this year. Approval of Iluvien would trigger a $25 million milestone payment to pSivida from Alimera and under the license agreement, pSivida also receives 20 percent of net profits on sales of Iluvien by Alimera.

finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext